Takeda reported that its oral TYK2 inhibitor zasocitinib (TAK-279) showed statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a Phase 3 top-line readout for moderate to severe plaque psoriasis. The data from Takeda’s Latitude Atlas study position zasocitinib as a potential next-generation oral option in a crowded TYK2 landscape. The competitive setup matters for both companies: Sotyktu was the first-in-class TYK2 therapy in its class, and Takeda’s results move its program into direct clinical and market comparison. For payers and prescribers, head-to-head positioning can accelerate formulary and sequencing decisions. The update arrives as psoriasis developers push for durable efficacy, safety differentiation, and convenience—factors that increasingly decide outcomes beyond the initial phase of regulatory review.